Advertisement
"We are very excited about the unsolicited case published in this month'sedition of Podiatry Management," states Cathy Bradshaw, President of WoundCare Innovations. "Diabetic foot wounds with infections can be complicatedand can require multiple approaches to treatment. This case demonstrates thebiocompatibility of CellerateRx(R) in supporting the successful take of livingskin equivalents and the delivery of antimicrobials when used in combinationaltherapies. The article further reports CellerateRx's(R) effectiveness intreating tunneling wounds, and is easy to use. Packing and unpacking thesetunneling wounds can be very painful for the patient. CellerateRx(R) isbiodegradable and does not need to be removed from the wound. We are delightedto be able to provide to the market a unique, patented advanced wound carecollagen product to assist in the management of these difficult wounds."
Advertisement
Diabetic wounds are problematic for patients and a drain on the healthcareindustry. In the United States, it is estimated that 15-20% of diabetics willdevelop a foot ulcer in their lifetime and that 14-24% of these ulcers willresult in amputations. Every 30 seconds a leg is lost to diabetes somewherein the world.
CellerateRx(R) is FDA cleared for acute and chronic wounds which includebut are not limited to: diabetic ulcers, venous stasis ulcers, ulcers due toarterial insufficiency, pressure ulcers stages I-IV, surgical wounds,traumatic wounds, superficial wounds, and 1st and 2nd degree burns. It comesin two forms, a powder which is about 95% collagen, and a gel which is about65% collagen, and contains no additives or synthetics. CellerateRx(R) ismanufactured in the United States.
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with itscorporate headquarters in Fort Worth, Texas, markets and distributes woundcare products to the healthcare market under patented technology licensed tothe Company. The Company is positioned and seeks to be a leading provider ofwound care products. For more information on the Company please visit theCompany's Website at www.Celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation ReformAct of 1995: The statements in the press release that relate to the company'sexpectations with regard to the future impact on the company's results fromnew products in development are "forward-looking statements," within themeaning of the Private Securities Litigation Reform Act of 1995. Since thisinformation may contain statements that involve risk and uncertainties and aresubject to change at any time, the company's actual results may differmaterially from expected results. This document may contain forward-lookingstatements concerning the Company's operations, current and future performanceand financial condition. These items involve risks and uncertainties such asproduct demand, market and customer acceptance, the effect of economicconditions, competition, pricing, the ability to consummate and integrateacquisitions, and other risks and uncertainties detailed in the Company's SECfilings. The Company undertakes no obligation to revise any of thesestatements to reflect the future circumstances or the occurrence ofunanticipated events.For Further Information: Product Information Shareholder Relations Cathy Bradshaw Lucy Singleton President Corporate Secretary 954-315-9242 817-820-7080
SOURCE Wound Management Technologies, Inc.
